P. Kent Hawryluk - Sep 16, 2024 Form 4 Insider Report for MBX Biosciences, Inc. (MBX)

Role: President & CEO, Director
Signature: /s/ Richard Bartram, attorney-in-fact
Stock symbol: MBX
Transactions as of: Sep 16, 2024
Transactions value $: $0
Form type: 4
Date filed: 9/17/2024, 08:07 PM
Previous filing: Sep 12, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MBX	Common Stock	Conversion of derivative security		+284K	+143.68%		481K	Sep 16, 2024	Direct	F1
transaction	MBX	Common Stock	Conversion of derivative security		+116K	+41.05%		398K	Sep 16, 2024	By Trust	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Shares	Change %	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	MBX	Series A Convertible Preferred Stock	Conversion of derivative security	-2.02M	-100%	Sep 16, 2024	Common Stock	168K	Direct	F1
transaction	MBX	Series A Convertible Preferred Stock	Conversion of derivative security	-346K	-100%	Sep 16, 2024	Common Stock	28.8K	By Trust	F1, F2
transaction	MBX	Series B Convertible Preferred Stock	Conversion of derivative security	-1.4M	-100%	Sep 16, 2024	Common Stock	116K	Direct	F1
transaction	MBX	Series B Convertible Preferred Stock	Conversion of derivative security	-77K	-100%	Sep 16, 2024	Common Stock	6.4K	By Trust	F1, F2
transaction	MBX	Series C Convertible Preferred Stock	Conversion of derivative security	-971K	-100%	Sep 16, 2024	Common Stock	80.8K	By Trust	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.
F2	Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Content

Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.

Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.